Retrospective observational cohort study of immune-related adverse events and survival among patients receiving ICIs for mNSCLC

Immune-related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy reportedly improve overall survival in patients with non-small cell lung cancer (NSCLC). However, studies have been small and the association between irAE severity and OS remains poorly defined. A retrospective cohort study in Alberta (Canada) found that among patients receiving any line ICIs for mNSCLC, developing a clinically meaningful irAE was associated with improved overall survival. This association was not compromised by hospitalization for severe toxic effects of irAEs.